참고문헌
- Ceeraz, S., E. C. Nowak, and R. J. Noelle. 2013. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 34: 556-563. https://doi.org/10.1016/j.it.2013.07.003
- Sharpe, A. H., and G. J. Freeman. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2: 116-126. https://doi.org/10.1038/nri727
- Sakaguchi, S., K. Wing, Y. Onishi, P. Prieto-Martin, and T. Yamaguchi. 2009. Regulatory T cells: how do they suppress immune responses? Int. Immunol. 21: 1105-1111. https://doi.org/10.1093/intimm/dxp095
- Grosso, J. F., and M. N. Jure-Kunkel. 2013. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 13: 5.
- Yang, Y. F., J. P. Zou, J. Mu, R. Wijesuriya, S. Ono, T. Walunas, J. Bluestone, H. Fujiwara, and T. Hamaoka. 1997. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 57: 4036-4041.
- Kwon, E. D., A. A. Hurwitz, B. A. Foster, C. Madias, A. L. Feldhaus, N. M. Greenberg, M. B. Burg, and J. P. Allison. 1997. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 94: 8099-8103. https://doi.org/10.1073/pnas.94.15.8099
- van, E. A., A. A. Hurwitz, and J. P. Allison. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190: 355-366. https://doi.org/10.1084/jem.190.3.355
- Demaria, S., N. Kawashima, A. M. Yang, M. L. Devitt, J. S. Babb, J. P. Allison, and S. C. Formenti. 2005. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11: 728-734.
- Hurwitz, A. A., T. F. Yu, D. R. Leach, and J. P. Allison. 1998. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. U. S. A. 95: 10067-10071. https://doi.org/10.1073/pnas.95.17.10067
- Mokyr, M. B., T. Kalinichenko, L. Gorelik, and J. A. Bluestone. 1998. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 58: 5301-5304.
- Waitz, R., S. B. Solomon, E. N. Petre, A. E. Trumble, M. Fasso, L. Norton, and J. P. Allison. 2012. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 72: 430-439. https://doi.org/10.1158/0008-5472.CAN-11-1782
- Phan, G. Q., J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, K. E. Morton, S. A. Mavroukakis, P. H. Duray, S. M. Steinberg, J. P. Allison, T. A. Davis, and S. A. Rosenberg. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U. S. A. 100: 8372-8377. https://doi.org/10.1073/pnas.1533209100
- Sanderson, K., R. Scotland, P. Lee, D. Liu, S. Groshen, J. Snively, S. Sian, G. Nichol, T. Davis, T. Keler, M. Yellin, and J. Weber. 2005. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23: 741-750. https://doi.org/10.1200/JCO.2005.01.128
- Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. van den Eertwegh, J. Lutzky, P. Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. H. Ottensmeier, C. Lebbe, C. Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. Hoos, and W. J. Urba. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363: 711-723. https://doi.org/10.1056/NEJMoa1003466
- Robert, C., L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, C. Lebbe, J. F. Baurain, A. Testori, J. J. Grob, N. Davidson, J. Richards, M. Maio, A. Hauschild, W. H. Miller, Jr., P. Gascon, M. Lotem, K. Harmankaya, R. Ibrahim, S. Francis, T. T. Chen, R. Humphrey, A. Hoos, and J. D. Wolchok. 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364: 2517-2526. https://doi.org/10.1056/NEJMoa1104621
- Ribas, A. 2008. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). Oncologist Suppl. 4: 10-15.
- Ribas, A., R. Kefford, M. A. Marshall, C. J. Punt, J. B. Haanen, M. Marmol, C. Garbe, H. Gogas, J. Schachter, G. Linette, P. Lorigan, K. L. Kendra, M. Maio, U. Trefzer, M. Smylie, G. A. McArthur, B. Dreno, P. D. Nathan, J. Mackiewicz, J. M. Kirkwood, J. Gomez-Navarro, B. Huang, D. Pavlov, and A. Hauschild. 2013. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31: 616-622. https://doi.org/10.1200/JCO.2012.44.6112
- Selby, M. J., J. J. Engelhardt, M. Quigley, K. A. Henning, T. Chen, M. Srinivasan, and A. J. Korman. 2013. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1: 32-42. https://doi.org/10.1158/2326-6066.CIR-13-0013
-
Yuan, J., M. Adamow, B. A. Ginsberg, T. S. Rasalan, E. Ritter, H. F. Gallardo, Y. Xu, E. Pogoriler, S. L. Terzulli, D. Kuk, K. S. Panageas, G. Ritter, M. Sznol, R. Halaban, A. A. Jungbluth, J. P. Allison, L. J. Old, J. D. Wolchok, and S. Gnjatic. 2011. Integrated NY-ESO-1 antibody and
$CD8^+$ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc. Natl. Acad. Sci. U. S. A. 108: 16723-16728. https://doi.org/10.1073/pnas.1110814108 -
Liakou, C. I., A. Kamat, D. N. Tang, H. Chen, J. Sun, P. Troncoso, C. Logothetis, and P. Sharma. 2008. CTLA-4 blockade increases IFNgamma-producing
$CD4^+ICOS^{hi}$ cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl. Acad. Sci. U. S. A. 105: 14987-14992. https://doi.org/10.1073/pnas.0806075105 - Keir, M. E., S. C. Liang, I. Guleria, Y. E. Latchman, A. Qipo, L. A. Albacker, M. Koulmanda, G. J. Freeman, M. H. Sayegh, and A. H. Sharpe. 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med. 203: 883-895. https://doi.org/10.1084/jem.20051776
- Larsson, M., E. M. Shankar, K. F. Che, A. Saeidi, R. Ellegard, M. Barathan, V. Velu, and A. Kamarulzaman. 2013. Molecular signatures of T-cell inhibition in HIV-1 infection. Retrovirology 10: 31. https://doi.org/10.1186/1742-4690-10-31
- Pardoll, D. M. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12: 252-264. https://doi.org/10.1038/nrc3239
- Ahmadzadeh, M., L. A. Johnson, B. Heemskerk, J. R. Wunderlich, M. E. Dudley, D. E. White, and S. A. Rosenberg. 2009. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114: 1537-1544. https://doi.org/10.1182/blood-2008-12-195792
- Matsuzaki, J., S. Gnjatic, P. Mhawech-Fauceglia, A. Beck, A. Miller, T. Tsuji, C. Eppolito, F. Qian, S. Lele, P. Shrikant, L. J. Old, and K. Odunsi. 2010. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 107: 7875-7880. https://doi.org/10.1073/pnas.1003345107
- Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687. https://doi.org/10.1038/nature04444
- Dong, H., S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano, D. B. Flies, P. C. Roche, J. Lu, G. Zhu, K. Tamada, V. A. Lennon, E. Celis, and L. Chen. 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8: 793-800.
- Iwai, Y., M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U. S. A. 99: 12293-12297. https://doi.org/10.1073/pnas.192461099
- Ghebeh, H., S. Mohammed, A. Al-Omair, A. Qattan, C. Lehe, G. Al-Qudaihi, N. Elkum, M. Alshabanah, A. S. Bin, A. Tulbah, D. Ajarim, T. Al-Tweigeri, and S. Dermime. 2006. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8: 190-198. https://doi.org/10.1593/neo.05733
- Steidl, C., S. P. Shah, B. W. Woolcock, L. Rui, M. Kawahara, P. Farinha, N. A. Johnson, Y. Zhao, A. Telenius, S. B. Neriah, A. McPherson, B. Meissner, U. C. Okoye, A. Diepstra, B. A. van den, M. Sun, G. Leung, S. J. Jones, J. M. Connors, D. G. Huntsman, K. J. Savage, L. M. Rimsza, D. E. Horsman, L. M. Staudt, U. Steidl, M. A. Marra, and R. D. Gascoyne. 2011. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471: 377-381. https://doi.org/10.1038/nature09754
- Rosenwald, A., G. Wright, K. Leroy, X. Yu, P. Gaulard, R. D. Gascoyne, W. C. Chan, T. Zhao, C. Haioun, T. C. Greiner, D. D. Weisenburger, J. C. Lynch, J. Vose, J. O. Armitage, E. B. Smeland, S. Kvaloy, H. Holte, J. Delabie, E. Campo, E. Montserrat, A. Lopez-Guillermo, G. Ott, H. K. Muller-Hermelink, J. M. Connors, R. Braziel, T. M. Grogan, R. I. Fisher, T. P. Miller, M. LeBlanc, M. Chiorazzi, H. Zhao, L. Yang, J. Powell, W. H. Wilson, E. S. Jaffe, R. Simon, R. D. Klausner, and L. M. Staudt. 2003. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198: 851-862. https://doi.org/10.1084/jem.20031074
- Hino, R., K. Kabashima, Y. Kato, H. Yagi, M. Nakamura, T. Honjo, T. Okazaki, and Y. Tokura. 2010. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116: 1757-1766. https://doi.org/10.1002/cncr.24899
- Gao, Q., X. Y. Wang, S. J. Qiu, I. Yamato, M. Sho, Y. Nakajima, J. Zhou, B. Z. Li, Y. H. Shi, Y. S. Xiao, Y. Xu, and J. Fan. 2009. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res. 15: 971-979. https://doi.org/10.1158/1078-0432.CCR-08-1608
- Muenst, S., A. R. Schaerli, F. Gao, S. Daster, E. Trella, R. A. Droeser, M. G. Muraro, P. Zajac, R. Zanetti, W. E. Gillanders, W. P. Weber, and S. D. Soysal. 2014. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res. Treat. 146: 15-24. https://doi.org/10.1007/s10549-014-2988-5
- Taube, J. M., R. A. Anders, G. D. Young, H. Xu, R. Sharma, T. L. McMiller, S. Chen, A. P. Klein, D. M. Pardoll, S. L. Topalian, and L. Chen. 2012. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4: 127ra37.
- Zheng, Z., Z. Bu, X. Liu, L. Zhang, Z. Li, A. Wu, X. Wu, X. Cheng, X. Xing, H. Du, X. Wang, Y. Hu, and J. Ji. 2014. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin. J. Cancer Res. 26: 104-111.
- Iwai, Y., S. Terawaki, and T. Honjo. 2005. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17: 133-144.
- Harvey, R. D. 2014. Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin. Pharmacol. Ther. 96: 214-223. https://doi.org/10.1038/clpt.2014.74
- Okudaira, K., R. Hokari, Y. Tsuzuki, Y. Okada, S. Komoto, C. Watanabe, C. Kurihara, A. Kawaguchi, S. Nagao, M. Azuma, H. Yagita, and S. Miura. 2009. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int. J. Oncol. 35: 741-749.
- Liu, X., J. X. Gao, J. Wen, L. Yin, O. Li, T. Zuo, T. F. Gajewski, Y. X. Fu, P. Zheng, and Y. Liu. 2003. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J. Exp. Med. 197: 1721-1730. https://doi.org/10.1084/jem.20022089
- Brahmer, J. R., C. G. Drake, I. Wollner, J. D. Powderly, J. Picus, W. H. Sharfman, E. Stankevich, A. Pons, T. M. Salay, T. L. McMiller, M. M. Gilson, C. Wang, M. Selby, J. M. Taube, R. Anders, L. Chen, A. J. Korman, D. M. Pardoll, I. Lowy, and S. L. Topalian. 2010. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28: 3167-3175. https://doi.org/10.1200/JCO.2009.26.7609
- Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton, and M. Sznol. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366: 2443-2454. https://doi.org/10.1056/NEJMoa1200690
- Hamid, O., C. Robert, A. Daud, F. S. Hodi, W. J. Hwu, R. Kefford, J. D. Wolchok, P. Hersey, R. W. Joseph, J. S. Weber, R. Dronca, T. C. Gangadhar, A. Patnaik, H. Zarour, A. M. Joshua, K. Gergich, J. Elassaiss-Schaap, A. Algazi, C. Mateus, P. Boasberg, P. C. Tumeh, B. Chmielowski, S. W. Ebbinghaus, X. N. Li, S. P. Kang, and A. Ribas. 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369: 134-144. https://doi.org/10.1056/NEJMoa1305133
- Brahmer, J. R., S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, H. C. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, S. Chen, T. M. Salay, S. Alaparthy, J. F. Grosso, A. J. Korman, S. M. Parker, S. Agrawal, S. M. Goldberg, D. M. Pardoll, A. Gupta, and J. M. Wigginton. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366: 2455-2465. https://doi.org/10.1056/NEJMoa1200694
- Wolchok, J. D., H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. Segal, C. E. Ariyan, R. A. Gordon, K. Reed, M. M. Burke, A. Caldwell, S. A. Kronenberg, B. U. Agunwamba, X. Zhang, I. Lowy, H. D. Inzunza, W. Feely, C. E. Horak, Q. Hong, A. J. Korman, J. M. Wigginton, A. Gupta, and M. Sznol. 2013. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369: 122-133. https://doi.org/10.1056/NEJMoa1302369
- Spranger, S., R. M. Spaapen, Y. Zha, J. Williams, Y. Meng, T. T. Ha, and T. F. Gajewski. 2013. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med. 5: 200ra116.
- Tafuri, A., A. Shahinian, F. Bladt, S. K. Yoshinaga, M. Jordana, A. Wakeham, L. M. Boucher, D. Bouchard, V. S. Chan, G. Duncan, B. Odermatt, A. Ho, A. Itie, T. Horan, J. S. Whoriskey, T. Pawson, J. M. Penninger, P. S. Ohashi, and T. W. Mak. 2001. ICOS is essential for effective T-helper-cell responses. Nature 409: 105-109. https://doi.org/10.1038/35051113
- McAdam, A. J., R. J. Greenwald, M. A. Levin, T. Chernova, N. Malenkovich, V. Ling, G. J. Freeman, and A. H. Sharpe. 2001. ICOS is critical for CD40-mediated antibody class switching. Nature 409: 102-105. https://doi.org/10.1038/35051107
- Parry, R. V., C. A. Rumbley, L. H. Vandenberghe, C. H. June, and J. L. Riley. 2003. CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J. Immunol. 171: 166-174. https://doi.org/10.4049/jimmunol.171.1.166
- Gigoux, M., J. Shang, Y. Pak, M. Xu, J. Choe, T. W. Mak, and W. K. Suh. 2009. Inducible costimulator promotes helper T-cell differentiation through phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. U. S. A. 106: 20371-20376. https://doi.org/10.1073/pnas.0911573106
- Gigoux, M., A. Lovato, J. Leconte, J. Leung, N. Sonenberg, and W. K. Suh. 2014. Inducible costimulator facilitates T-dependent B cell activation by augmenting IL-4 translation. Mol. Immunol. 59: 46-54. https://doi.org/10.1016/j.molimm.2014.01.008
- Rolf, J., K. Fairfax, and M. Turner. 2010. Signaling pathways in T follicular helper cells. J. Immunol. 184: 6563-6568. https://doi.org/10.4049/jimmunol.1000202
- Greenwald, R. J., G. J. Freeman, and A. H. Sharpe. 2005. The B7 family revisited. Annu. Rev. Immunol. 23: 515-548. https://doi.org/10.1146/annurev.immunol.23.021704.115611
- Lee, H., J. H. Kim, S. Y. Yang, J. Kong, M. Oh, D. H. Jeong, J. I. Chung, K. B. Bae, J. Y. Shin, K. H. Hong, and I. Choi. 2010. Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients. J. Cancer Res. Clin. Oncol. 136: 1445-1452. https://doi.org/10.1007/s00432-010-0800-4
- Bogunovic, D., D. W. O'Neill, I. Belitskaya-Levy, V. Vacic, Y. L. Yu, S. Adams, F. Darvishian, R. Berman, R. Shapiro, A. C. Pavlick, S. Lonardi, J. Zavadil, I. Osman, and N. Bhardwaj. 2009. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc. Natl. Acad. Sci. U. S. A. 106: 20429-20434. https://doi.org/10.1073/pnas.0905139106
- Tamura, H., K. Dan, K. Tamada, K. Nakamura, Y. Shioi, H. Hyodo, S. D. Wang, H. Dong, L. Chen, and K. Ogata. 2005. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin. Cancer Res. 11: 5708-5717. https://doi.org/10.1158/1078-0432.CCR-04-2672
- Martin-Orozco, N., Y. Li, Y. Wang, S. Liu, P. Hwu, Y. J. Liu, C. Dong, and L. Radvanyi. 2010. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res. 70: 9581-9590. https://doi.org/10.1158/0008-5472.CAN-10-1379
-
Sim, G. C., N. Martin-Orozco, L. Jin, Y. Yang, S. Wu, E. Washington, D. Sanders, C. Lacey, Y. Wang, L. Vence, P. Hwu, and L. Radvanyi. 2014. IL-2 therapy promotes suppressive
$ICOS^+$ Treg expansion in melanoma patients. J. Clin. Invest. 124: 99-110. https://doi.org/10.1172/JCI46266 - Carthon, B. C., J. D. Wolchok, J. Yuan, A. Kamat, D. S. Ng Tang, J. Sun, G. Ku, P. Troncoso, C. J. Logothetis, J. P. Allison, and P. Sharma. 2010. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16: 2861-2871. https://doi.org/10.1158/1078-0432.CCR-10-0569
- Vonderheide, R. H., P. M. LoRusso, M. Khalil, E. M. Gartner, D. Khaira, D. Soulieres, P. Dorazio, J. A. Trosko, J. Ruter, G. L. Mariani, T. Usari, and S. M. Domchek. 2010. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res. 16: 3485-3494. https://doi.org/10.1158/1078-0432.CCR-10-0505
- Fu, T., Q. He, and P. Sharma. 2011. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res. 71: 5445-5454. https://doi.org/10.1158/0008-5472.CAN-11-1138
- Guedan, S., X. Chen, A. Madar, C. Carpenito, S. E. McGettigan, M. J. Frigault, J. Lee, A. D. Posey, Jr., J. Scholler, N. Scholler, R. Bonneau, and C. H. June. 2014. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood 124: 1070-1080. https://doi.org/10.1182/blood-2013-10-535245
- Hashiguchi, M., H. Kobori, P. Ritprajak, Y. Kamimura, H. Kozono, and M. Azuma. 2008. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc. Natl. Acad. Sci. U. S. A. 105: 10495-10500. https://doi.org/10.1073/pnas.0802423105
- Leitner, J., C. Klauser, W. F. Pickl, J. Stockl, O. Majdic, A. F. Bardet, D. P. Kreil, C. Dong, T. Yamazaki, G. Zlabinger, K. Pfistershammer, and P. Steinberger. 2009. B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur. J. Immunol. 39: 1754-1764. https://doi.org/10.1002/eji.200839028
- Chapoval, A. I., J. Ni, J. S. Lau, R. A. Wilcox, D. B. Flies, D. Liu, H. Dong, G. L. Sica, G. Zhu, K. Tamada, and L. Chen. 2001. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol. 2: 269-274. https://doi.org/10.1038/85339
- Suh, W. K., B. U. Gajewska, H. Okada, M. A. Gronski, E. M. Bertram, W. Dawicki, G. S. Duncan, J. Bukczynski, S. Plyte, A. Elia, A. Wakeham, A. Itie, S. Chung, C. J. Da, S. Arya, T. Horan, P. Campbell, K. Gaida, P. S. Ohashi, T. H. Watts, S. K. Yoshinaga, M. R. Bray, M. Jordana, and T. W. Mak. 2003. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat. Immunol. 4: 899-906. https://doi.org/10.1038/ni967
- Wang, L., C. C. Fraser, K. Kikly, A. D. Wells, R. Han, A. J. Coyle, L. Chen, and W. W. Hancock. 2005. B7-H3 promotes acute and chronic allograft rejection. Eur. J. Immunol. 35: 428-438. https://doi.org/10.1002/eji.200425518
- Prasad, D. V., T. Nguyen, Z. Li, Y. Yang, J. Duong, Y. Wang, and C. Dong. 2004. Murine B7-H3 is a negative regulator of T cells. J. Immunol. 173: 2500-2506. https://doi.org/10.4049/jimmunol.173.4.2500
- Collins, M., V. Ling, and B. M. Carreno. 2005. The B7 family of immune-regulatory ligands. Genome Biol. 6: 223. https://doi.org/10.1186/gb-2005-6-6-223
- Loos, M., D. M. Hedderich, H. Friess, and J. Kleeff. 2010. B7-h3 and its role in antitumor immunity. Clin. Dev. Immunol. 2010: 683875.
-
Luo, L., A. I. Chapoval, D. B. Flies, G. Zhu, F. Hirano, S. Wang, J. S. Lau, H. Dong, K. Tamada, A. S. Flies, Y. Liu, and L. Chen. 2004. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific
$CD8^+$ cytolytic T cells. J. Immunol. 173: 5445-5450. https://doi.org/10.4049/jimmunol.173.9.5445 - Sun, X., M. Vale, E. Leung, J. R. Kanwar, R. Gupta, and G. W. Krissansen. 2003. Mouse B7-H3 induces antitumor immunity. Gene Ther. 10: 1728-1734. https://doi.org/10.1038/sj.gt.3302070
- Loos, M., D. M. Hedderich, M. Ottenhausen, N. A. Giese, M. Laschinger, I. Esposito, J. Kleeff, and H. Friess. 2009. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 9: 463. https://doi.org/10.1186/1471-2407-9-463
- Wu, C. P., J. T. Jiang, M. Tan, Y. B. Zhu, M. Ji, K. F. Xu, J. M. Zhao, G. B. Zhang, and X. G. Zhang. 2006. Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J. Gastroenterol. 12: 457-459. https://doi.org/10.3748/wjg.v12.i3.457
- Zang, X., R. H. Thompson, H. A. Al-Ahmadie, A. M. Serio, V. E. Reuter, J. A. Eastham, P. T. Scardino, P. Sharma, and J. P. Allison. 2007. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc. Natl. Acad. Sci. U. S. A. 104: 19458-19463. https://doi.org/10.1073/pnas.0709802104
- Roth, T. J., Y. Sheinin, C. M. Lohse, S. M. Kuntz, X. Frigola, B. A. Inman, A. E. Krambeck, M. E. McKenney, R. J. Karnes, M. L. Blute, J. C. Cheville, T. J. Sebo, and E. D. Kwon. 2007. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 67: 7893-7900. https://doi.org/10.1158/0008-5472.CAN-07-1068
- Sun, J., L. J. Chen, G. B. Zhang, J. T. Jiang, M. Zhu, Y. Tan, H. T. Wang, B. F. Lu, and X. G. Zhang. 2010. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol. Immunother. 59: 1163-1171. https://doi.org/10.1007/s00262-010-0841-1
- Xu, H., I. Y. Cheung, H. F. Guo, and N. K. Cheung. 2009. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 69: 6275-6281. https://doi.org/10.1158/0008-5472.CAN-08-4517
- Sica, G. L., I. H. Choi, G. Zhu, K. Tamada, S. D. Wang, H. Tamura, A. I. Chapoval, D. B. Flies, J. Bajorath, and L. Chen. 2003. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18: 849-861. https://doi.org/10.1016/S1074-7613(03)00152-3
- Choi, I. H., G. Zhu, G. L. Sica, S. E. Strome, J. C. Cheville, J. S. Lau, Y. Zhu, D. B. Flies, K. Tamada, and L. Chen. 2003. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 171: 4650-4654. https://doi.org/10.4049/jimmunol.171.9.4650
- Kryczek, I., L. Zou, P. Rodriguez, G. Zhu, S. Wei, P. Mottram, M. Brumlik, P. Cheng, T. Curiel, L. Myers, A. Lackner, X. Alvarez, A. Ochoa, L. Chen, and W. Zou. 2006. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203: 871-881. https://doi.org/10.1084/jem.20050930
- Zang, X., P. Loke, J. Kim, K. Murphy, R. Waitz, and J. P. Allison. 2003. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc. Natl. Acad. Sci. U. S. A. 100: 10388-10392. https://doi.org/10.1073/pnas.1434299100
- Ou, D., X. Wang, D. L. Metzger, Z. Ao, P. Pozzilli, R. F. James, L. Chen, and G. L. Warnock. 2006. Suppression of human T-cell responses to beta-cells by activation of B7-H4 pathway. Cell Transplant. 15: 399-410. https://doi.org/10.3727/000000006783981837
- Suh, W. K., S. Wang, G. S. Duncan, Y. Miyazaki, E. Cates, T. Walker, B. U. Gajewska, E. Deenick, W. Dawicki, H. Okada, A. Wakeham, A. Itie, T. H. Watts, P. S. Ohashi, M. Jordana, H. Yoshida, and T. W. Mak. 2006. Generation and characterization of B7-H4/B7S1/B7x-deficient mice. Mol. Cell Biol. 26: 6403-6411. https://doi.org/10.1128/MCB.00755-06
- Zhu, G., M. M. Augustine, T. Azuma, L. Luo, S. Yao, S. Anand, A. C. Rietz, J. Huang, H. Xu, A. S. Flies, S. J. Flies, K. Tamada, M. Colonna, J. M. van Deursen, and L. Chen. 2009. B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. Blood 113: 1759-1767. https://doi.org/10.1182/blood-2008-01-133223
- Leung, J., and W. K. Suh. 2013. Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model. J. Immunol. 190: 6651-6661. https://doi.org/10.4049/jimmunol.1201242
- Cheng, L., J. Jiang, R. Gao, S. Wei, F. Nan, S. Li, and B. Kong. 2009. B7-H4 expression promotes tumorigenesis in ovarian cancer. Int. J. Gynecol. Cancer 19: 1481-1486. https://doi.org/10.1111/IGC.0b013e3181ad0fa2
- Salceda, S., T. Tang, M. Kmet, A. Munteanu, M. Ghosh, R. Macina, W. Liu, G. Pilkington, and J. Papkoff. 2005. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp. Cell Res. 306: 128-141. https://doi.org/10.1016/j.yexcr.2005.01.018
- Sedy, J. R., M. Gavrieli, K. G. Potter, M. A. Hurchla, R. C. Lindsley, K. Hildner, S. Scheu, K. Pfeffer, C. F. Ware, T. L. Murphy, and K. M. Murphy. 2005. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat. Immunol. 6: 90-98. https://doi.org/10.1038/ni1144
- Abadi, Y. M., H. Jeon, K. C. Ohaegbulam, L. Scandiuzzi, K. Ghosh, K. A. Hofmeyer, J. S. Lee, A. Ray, C. Gravekamp, and X. Zang. 2013. Host b7x promotes pulmonary metastasis of breast cancer. J. Immunol. 190: 3806-3814. https://doi.org/10.4049/jimmunol.1202439
- He, C., H. Qiao, H. Jiang, and X. Sun. 2011. The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival. Clin. Dev. Immunol. 2011: 695834.
- Tringler, B., S. Zhuo, G. Pilkington, K. C. Torkko, M. Singh, M. S. Lucia, D. E. Heinz, J. Papkoff, and K. R. Shroyer. 2005. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin. Cancer Res. 11: 1842-1848. https://doi.org/10.1158/1078-0432.CCR-04-1658
- Bignotti, E., R. A. Tassi, S. Calza, A. Ravaggi, C. Romani, E. Rossi, M. Falchetti, F. E. Odicino, S. Pecorelli, and A. D. Santin. 2006. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol. Oncol. 103: 405-416. https://doi.org/10.1016/j.ygyno.2006.03.056
- Le, H. K., L. Graham, E. Cha, J. K. Morales, M. H. Manjili, and H. D. Bear. 2009. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int. Immunopharmacol. 9: 900-909. https://doi.org/10.1016/j.intimp.2009.03.015
- Dangaj, D., E. Lanitis, A. Zhao, S. Joshi, Y. Cheng, R. Sandaltzopoulos, H. J. Ra, G. net-Desnoyers, D. J. Powell, Jr., and N. Scholler. 2013. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. Cancer Res. 73: 4820-4829. https://doi.org/10.1158/0008-5472.CAN-12-3457
- Le, M., I, W. Chen, J. L. Lines, M. Day, J. Li, P. Sergent, R. J. Noelle, and L. Wang. 2014. VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Res. 74: 1933-1944. https://doi.org/10.1158/0008-5472.CAN-13-1506
- Zhao, R., J. M. Chinai, S. Buhl, L. Scandiuzzi, A. Ray, H. Jeon, K. C. Ohaegbulam, K. Ghosh, A. Zhao, M. D. Scharff, and X. Zang. 2013. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc. Natl. Acad. Sci. U. S. A. 110: 9879-9884. https://doi.org/10.1073/pnas.1303524110
- Brandt, C. S., M. Baratin, E. C. Yi, J. Kennedy, Z. Gao, B. Fox, B. Haldeman, C. D. Ostrander, T. Kaifu, C. Chabannon, A. Moretta, R. West, W. Xu, E. Vivier, and S. D. Levin. 2009. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206: 1495-1503. https://doi.org/10.1084/jem.20090681
피인용 문헌
- Inhibitory immunologicznych punktów kontrolnych podziału komórki w leczeniu chorób nowotworowych vol.47, pp.2, 2014, https://doi.org/10.1016/j.achaem.2016.04.008
- Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer vol.5, pp.8, 2014, https://doi.org/10.1080/2162402x.2016.1207841
- Assessment of combined expression of B7-H3 and B7-H4 as prognostic marker in esophageal cancer patients vol.7, pp.47, 2014, https://doi.org/10.18632/oncotarget.12628
- Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors vol.7, pp.6, 2014, https://doi.org/10.18632/oncotarget.6902
- Knockdown of B7-H6 inhibits tumor progression and enhances chemosensitivity in B-cell non-Hodgkin lymphoma vol.48, pp.4, 2014, https://doi.org/10.3892/ijo.2016.3393
- SKAP2 Promotes Podosome Formation to Facilitate Tumor-Associated Macrophage Infiltration and Metastatic Progression vol.76, pp.2, 2016, https://doi.org/10.1158/0008-5472.can-15-1879
- Immunotherapy for advanced melanoma: future directions vol.8, pp.2, 2016, https://doi.org/10.2217/imt.15.111
- MUC1 immunotherapy against a metastatic mammary adenocarcinoma model: Importance of IFN-gamma vol.37, pp.1, 2014, https://doi.org/10.1515/prilozi-2016-0001
- The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma vol.37, pp.11, 2016, https://doi.org/10.1007/s13277-016-5386-2
- Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis vol.14, pp.1, 2016, https://doi.org/10.1186/s12916-016-0635-1
- Improved osteogenesis and upregulated immunogenicity in human placenta-derived mesenchymal stem cells primed with osteogenic induction medium vol.7, pp.1, 2016, https://doi.org/10.1186/s13287-016-0400-6
- Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model vol.66, pp.4, 2014, https://doi.org/10.1007/s00262-016-1950-2
- Recent Advances in Aptamers Targeting Immune System vol.40, pp.1, 2014, https://doi.org/10.1007/s10753-016-0437-9
- Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications vol.6, pp.12, 2017, https://doi.org/10.1080/2162402x.2017.1371896
- B7-H3 promotes the proliferation, migration and invasiveness of cervical cancer cells and is an indicator of poor prognosis vol.38, pp.2, 2014, https://doi.org/10.3892/or.2017.5730
- Immunoregulatory protein B7‐H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells vol.30, pp.5, 2014, https://doi.org/10.1111/pcmr.12599
- B7-H3 in tumors: friend or foe for tumor immunity? vol.81, pp.2, 2014, https://doi.org/10.1007/s00280-017-3508-1
- QSAR, docking, ADMET, and system pharmacology studies on tormentic acid derivatives for anticancer activity vol.36, pp.9, 2018, https://doi.org/10.1080/07391102.2017.1355846
- Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy vol.22, pp.4, 2014, https://doi.org/10.1080/14728222.2018.1444753
- Expression of Programmed Death-Ligand 1 by Human Colonic CD90 + Stromal Cells Differs Between Ulcerative Colitis and Crohn’s Disease and Determines Their Capacity to Suppress Th1 Cells vol.9, pp.None, 2018, https://doi.org/10.3389/fimmu.2018.01125
- Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology vol.9, pp.None, 2014, https://doi.org/10.3389/fimmu.2018.02582
- A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer vol.5, pp.None, 2018, https://doi.org/10.3389/fnut.2018.00138
- Knockdown of B7H6 inhibits tumor progression in triple-negative breast cancer vol.16, pp.1, 2014, https://doi.org/10.3892/ol.2018.8689
- PD-1/PD-L1 in disease vol.10, pp.2, 2014, https://doi.org/10.2217/imt-2017-0120
- CCL5-deficiency enhances intratumoral infiltration of CD8 + T cells in colorectal cancer vol.9, pp.7, 2014, https://doi.org/10.1038/s41419-018-0796-2
- B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration vol.40, pp.11, 2014, https://doi.org/10.1177/1010428318815032
- Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer vol.4, pp.None, 2018, https://doi.org/10.1038/s41523-018-0095-1
- Analysis of the Expression and Regulation of PD-1 Protein on the Surface of Myeloid-Derived Suppressor Cells (MDSCs) vol.27, pp.1, 2014, https://doi.org/10.4062/biomolther.2018.201
- High expression of B7-H2 or B7-H3 is associated with poor prognosis in hepatocellular carcinoma vol.19, pp.5, 2019, https://doi.org/10.3892/mmr.2019.10080
- B7-CD28 gene family expression is associated with prognostic and immunological characteristics of diffuse large B-cell lymphoma vol.11, pp.12, 2014, https://doi.org/10.18632/aging.102025
- Inducible T‐cell co‐stimulator: Signaling mechanisms in T follicular helper cells and beyond vol.291, pp.1, 2014, https://doi.org/10.1111/imr.12771
- B7-H3 and B7-H4 Expression in Breast Cancer and Their Association with Clinicopathological Variables and T Cell Infiltration vol.87, pp.3, 2014, https://doi.org/10.1159/000505756
- Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines vol.94, pp.3, 2020, https://doi.org/10.1128/jvi.01677-19
- B7-1 and GM-CSF enhance the anti-tumor immune effect of DC-tumor fusion vaccine in the treatment of prostate cancer vol.37, pp.11, 2014, https://doi.org/10.1007/s12032-020-01433-2